Economist at the University of Chicago who served as acting chairman of the Council of Economic Advisers during President Donald Trump's first term.
Philipson has argued that European and other rich countries consistently underspend on innovative medicines, shifting the burden of paying for medical progress onto Americans. He advocates a NATO-style spending framework in which high-income countries adopt minimum-spending targets for innovative medicines—specifically, matching America's per-head share of GDP (nearly 0.8%). He contends that if Italy, Spain, Germany and France alone matched that share, biopharmaceutical revenues would jump by tens of billions of dollars, yielding more new drugs.
There was a new library in the Civic Centre. It was so new it didn't even have librarians. It had Assistant Information Officers.